Actelion announces "remarkable" PGI2 receptor agonist data
17 July 2009 00:00 in Pharmaceutical Company Product News
Actelion has announced positive data from a study relating to its orally active non-prostanoid PGI2 receptor agonist in patients with pulmonary arterial hypertension (PAH).
In a statement, the organisation explained that the placebo-controlled, double-blind trial, which involved 43 patients, was undertaken to determine the tolerability, safety and efficacy of the therapy.
The company said the study was met with "high statistical significance" and the compound was found to be "well tolerated".
Commenting, Jean-Paul Clozel, managing director and chief executive of Actelion, said the combination of high efficacy and good tolerability means that the firm is determined to accelerate its development programme for the therapy.
"Together with our partner Nippon Shinyaku, we are very excited by the remarkable results we have seen in this study," he added.
Earlier this month, the company announced that its paediatric formulation of Tracleer (bosentan) has been approved for the treatment of PAH in children in the EU.
Other news stories from 17/07/2009
Related news
Read more in the Zenopa News Archive
How this news is generated
Story collated for Zenopa by the Adfero News Agency
